Cubist Systematic Strategies LLC Reduces Stake in Immunome, Inc. (NASDAQ:IMNM)

Cubist Systematic Strategies LLC reduced its position in Immunome, Inc. (NASDAQ:IMNM) by 73.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 19,421 shares of the company’s stock after selling 54,117 shares during the period. Cubist Systematic Strategies LLC’s holdings in Immunome were worth $235,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Quest Partners LLC purchased a new position in shares of Immunome in the 2nd quarter worth $81,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Immunome during the second quarter valued at $97,000. Arizona State Retirement System lifted its position in Immunome by 9.2% during the second quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock valued at $131,000 after purchasing an additional 918 shares in the last quarter. EntryPoint Capital LLC lifted its position in Immunome by 21,864.0% during the first quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock valued at $136,000 after purchasing an additional 5,466 shares in the last quarter. Finally, AQR Capital Management LLC lifted its position in Immunome by 34.6% during the second quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock valued at $194,000 after purchasing an additional 4,129 shares in the last quarter. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Immunome Stock Down 0.7 %

NASDAQ:IMNM opened at $12.15 on Tuesday. The business’s 50-day simple moving average is $14.14 and its two-hundred day simple moving average is $14.80. The stock has a market cap of $728.62 million, a PE ratio of -1.61 and a beta of 1.76. Immunome, Inc. has a 52 week low of $6.93 and a 52 week high of $30.96.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.11). Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. The business had revenue of $2.36 million for the quarter, compared to the consensus estimate of $2.62 million. Sell-side analysts anticipate that Immunome, Inc. will post -1.92 earnings per share for the current fiscal year.

Insider Transactions at Immunome

In other news, Director Jean Jacques Bienaime bought 7,000 shares of Immunome stock in a transaction dated Friday, August 16th. The shares were purchased at an average cost of $13.94 per share, with a total value of $97,580.00. Following the completion of the acquisition, the director now owns 16,615 shares of the company’s stock, valued at $231,613.10. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Jean Jacques Bienaime bought 7,000 shares of Immunome stock in a transaction dated Friday, August 16th. The shares were purchased at an average cost of $13.94 per share, with a total value of $97,580.00. Following the completion of the acquisition, the director now owns 16,615 shares of the company’s stock, valued at $231,613.10. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jack Higgins sold 3,524 shares of Immunome stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $13.93, for a total value of $49,089.32. Following the completion of the sale, the insider now directly owns 16,000 shares in the company, valued at $222,880. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 8.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on IMNM. Piper Sandler lowered their target price on Immunome from $27.00 to $23.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 13th. Wedbush reiterated an “outperform” rating and set a $33.00 target price on shares of Immunome in a research report on Tuesday, August 13th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $29.00.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.